Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Kirsten Rønholt1, Stine Simonsen2, Farnam Barati Sedeh3

  • 1Afdeling for Hud- og Kønssygdomme, Aarhus Universitetshospital.

Ugeskrift for Laeger
|November 29, 2023
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-life tonsillectomy and subsequent risk of psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Prevalence of Steatotic Liver Disease with Fibrosis and Diagnostic Screening Tools in Patients with Psoriasis.

Acta dermato-venereologica·2026
Same author

Psoriasis Triggers and Disease Activity: Analysis of Survey Data from the PSODEEP1 Study.

Acta dermato-venereologica·2026
Same author

Intraocular Pressure During Short-Term Topical or Systemic Corticosteroid Treatment: Analysis of 3 Randomized Clinical Trials.

JAMA dermatology·2026
Same author

Anakinra alters epidermal tissue-resident memory T-cell profiles but fails to reduce clinical responses upon nickel rechallenge in individuals with nickel allergy.

The Journal of investigative dermatology·2026
Same author

Preterm Birth Is Associated with Reduced Risk of Atopic Dermatitis and a Distinct Allergic Comorbidity Profile in Early Childhood.

The British journal of dermatology·2026

Alopecia areata is an unpredictable autoimmune disease causing hair loss. The recent approval of baricitinib marks a new era for targeted treatments.

Area of Science:

  • Immunodermatology
  • Autoimmune disorders
  • Hair follicle biology

Background:

  • Alopecia areata (AA) is an autoimmune condition characterized by inflammation at the hair follicle base, leading to non-scarring hair loss.
  • The disease presents with variable clinical manifestations, ranging from localized scalp patches to complete body hair loss (alopecia universalis).
  • Understanding the unpredictable course and heterogeneity of AA is crucial for effective patient management.

Approach:

  • This review synthesizes current knowledge on the pathogenesis and clinical spectrum of alopecia areata.
  • It examines the disease's variable progression and impact on patients.
  • The review highlights recent therapeutic advancements and future research directions.

Key Points:

  • Inflammation targeting the hair follicle is the primary mechanism in alopecia areata.

Related Experiment Videos

  • The disease course is highly variable and unpredictable.
  • The 2022 approval of baricitinib, a JAK-inhibitor, signifies a breakthrough in targeted AA therapy.

    • Conclusions:

    • Alopecia areata requires further research into its complex autoimmune mechanisms.
    • The development of pathogenesis-specific treatments is essential for improving patient outcomes.
    • Baricitinib's approval opens avenues for novel therapeutic strategies targeting the underlying disease processes.